First American Bank Has $8.52 Million Holdings in Eli Lilly And Co (NYSE:LLY)

First American Bank lowered its position in shares of Eli Lilly And Co (NYSE:LLY) by 13.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 65,617 shares of the company’s stock after selling 10,527 shares during the period. First American Bank’s holdings in Eli Lilly And Co were worth $8,515,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Captrust Financial Advisors increased its holdings in shares of Eli Lilly And Co by 0.4% in the fourth quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock worth $2,503,000 after buying an additional 87 shares during the period. Bronfman E.L. Rothschild L.P. increased its holdings in shares of Eli Lilly And Co by 1.6% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock worth $641,000 after buying an additional 87 shares during the period. First Personal Financial Services increased its holdings in shares of Eli Lilly And Co by 2.3% in the fourth quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock worth $455,000 after buying an additional 89 shares during the period. Carroll Financial Associates Inc. increased its holdings in shares of Eli Lilly And Co by 1.3% in the fourth quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock worth $810,000 after buying an additional 91 shares during the period. Finally, Bailard Inc. increased its holdings in shares of Eli Lilly And Co by 3.6% in the fourth quarter. Bailard Inc. now owns 2,672 shares of the company’s stock worth $309,000 after buying an additional 92 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently commented on LLY. Citigroup set a $124.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a report on Tuesday, February 26th. Cantor Fitzgerald reiterated a “buy” rating on shares of Eli Lilly And Co in a report on Monday, February 4th. Argus restated a “buy” rating on shares of Eli Lilly And Co in a report on Thursday, December 27th. Guggenheim downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price target on the stock. in a report on Thursday, April 11th. Finally, Barclays restated a “buy” rating and set a $140.00 price target on shares of Eli Lilly And Co in a report on Sunday, April 14th. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $117.89.

In related news, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total value of $480,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Enrique A. Conterno sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $121.00, for a total value of $3,025,000.00. The disclosure for this sale can be found here. Insiders sold a total of 867,382 shares of company stock worth $109,265,182 over the last ninety days. 0.11% of the stock is currently owned by insiders.

Shares of LLY traded up $1.64 during mid-day trading on Friday, reaching $119.87. The company had a trading volume of 3,325,884 shares, compared to its average volume of 14,395,921. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07. Eli Lilly And Co has a 52 week low of $77.09 and a 52 week high of $132.13. The stock has a market cap of $121.70 billion, a P/E ratio of 21.60, a P/E/G ratio of 2.23 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). The company had revenue of $6.44 billion during the quarter, compared to the consensus estimate of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. On average, equities analysts anticipate that Eli Lilly And Co will post 5.66 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/27/first-american-bank-lowers-stake-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: How Investors Can Profit from Options Trading

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.